• Liquidia recently reported preliminary 2025 results showing strong uptake of its newly launched pulmonary hypertension drug YUTREPIA, with over 2,800 unique patient prescriptions and US$148.30 million in net product sales, including US$90.10 million in the fourth quarter alone.
• An interesting angle for investors is that YUTREPIA’s performance has already generated over US$30.00 million in positive fourth-quarter cash flow, giving Liquidia additional financial flexibility to expand its salesforce and fund further clinical development of both YUTREPIA and its investigational candidate L606.
• Against this backdrop, we’ll examine how YUTREPIA’s rapid prescription uptake shapes Liquidia’s investment narrative and future growth considerations for investors.

These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Liquidia's Investment Narrative?

For someone considering Liquidia today, the core belief is that YUTREPIA can anchor a durable pulmonary hypertension franchise while the company manages its legal, reimbursement and execution hurdles. The latest preliminary 2025 numbers, with US$148.30 million in YUTREPIA sales and positive fourth quarter cash flow, strengthen the near term story by easing funding pressures around the sales buildout and pipeline work on L606. At the same time, the recent share volatility, Needham removing Liquidia from its 2026 Conviction List and market focus on profitability and insider selling underline that confidence is still conditional on sustaining prescription growth and avoiding adverse court outcomes. For now, this news mostly sharpens existing catalysts and risks rather than creating new ones, but it raises the stakes on each of them. However, one particular source of uncertainty remains critical for shareholders to understand.

Liquidia's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community span roughly US$2 to just under US$200 per share, underlining how far apart individual views can be. Set against Liquidia’s dependence on YUTREPIA execution and ongoing litigation risk, this spread invites you to weigh several very different scenarios for how the story could unfold.

Explore 5 other fair value estimates on Liquidia - why the stock might be worth over 5x more than the current price!

Build Your Own Liquidia Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Liquidia research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Liquidia research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Liquidia's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 39 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.